Super Zdrowie Spółka z Ograniczoną Odpowiedzialnością (KRS 0000414192, NIP 5242751089) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. Super Zdrowie operates in: Dispensing chemist in specialised stores (PKD 47.73.Z). Industry: Retail trade. The company has been listed in the National Court Register since March 13, 2012. Super Zdrowie's most recently reported net revenue was 37.8 M PLN for 2024.
Negative equity
Negative equity in 2 of 8 available reporting years.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Super Zdrowie
Identity
- Name
- Super Zdrowie Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- March 13, 2012
- Registry status as of
- May 17, 2026
- Latest entry
- May 17, 2026
- Founding act
- 29.02.2012R, NOTARIUSZ W WARSZAWIE GRZEGORZ KUZARA ZA REP A 693/2012
Articles of association history (2)
- February 29, 2012: 29.02.2012R, NOTARIUSZ W WARSZAWIE GRZEGORZ KUZARA ZA REP A 693/2012
- June 14, 2022: 14.06.2022 R., NOTARIUSZ BARTŁOMIEJ JANICKI, REPERTORIUM A NR 3707/2022, UCHYLENIE WSZYSTKICH DOTYCHCZASOWYCH POSTANOWIEŃ UMOWY SPÓŁKI I ICH MIEJSCE PRZYJĘCIE NOWYCH POSTANOWIEŃ PAR. 1 - 27 UMOWY SPÓŁKI
Activities
Other activities
Address and contact
- Address
- ALEJE JEROZOLIMSKIE, 134, 02-305, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-99872-55319-GSFGH-24
Risk and payment profile - Super Zdrowie
Credibility rating
80.6 / 100
Very good credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
Spółka wykazuje sygnały niestabilności organizacyjnej: częste zmiany w zarządzie. Może to wskazywać na podwyższone ryzyko współpracy.
Shareholder changes
3
3/14 yrs
Board changes
12
12/14 yrs
PKD changes
2
2/14 yrs
Name changes
0
0/14 yrs
Data from 14 years of registry activity.
Credibility history
Payment reliability score from 2017–2024
Current: B (81/100)
Trend: stable (+1.3 pts/year)
High payment credibility - the company's financial condition is good and the risk of cooperating with it is low.
Trade credit limit history
Standard limit from 2017–2024
Current: 4.3 M PLN
Safe: 2.8 M PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Super Zdrowie
Founded
March 13, 2012
14 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
47.73.Z
Dispensing chemist in specialised stores
Share capital
105.0 K PLN
2,100 shares total
Shareholders
1
shareholder
Board
3 people
Filed years
8 years
2017–2024 · profitable: 5/8
Registry entries
48
latest: May 17, 2026
Risk signals
Revenue
37.8 M PLN
2024
Net profit
2.2 M PLN
2024
Assets
16.0 M PLN
2024
Equity
8.2 M PLN
2024
EBITDA
2.6 M PLN
2024
Valuation
15.0 M PLN
High confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Super Zdrowie.
No ratings
Related articles
News
Ambra in 2026: PLN 48.1m capex (+212%), a PLN 1.10 dividend three years running, Cydr Lubelski and Romanian Zarea as the premium engines
Warsaw-based Ambra S.A. (KRS 0000041726, ul. Puławska 336) closed H1 of fiscal 2025/2026 with PLN 556.8m of revenue and PLN 49.0m of net profit, while raising capex by 212% to PLN 48.1m - mainly for the soft-drinks line in Wola Duża and the PLN 11.9m acquisition of a Romanian company. Despite the heavy investment cycle the board is keeping the PLN 1.10 dividend per share for the third year running (~5.9% yield).
News
Answear in 2026: first full year without MCI, PLN 9.3 m net profit, but the supervisory board cuts the 2026 EBITDA target from PLN 100 m to PLN 90 m
Kraków-based Answear.com S.A. (KRS 0000816066) closed 2025 with revenue of PLN 1.7bn (+13% YoY), EBITDA of PLN 56m (+63%) and net profit of PLN 9.3m - a return to the black after a PLN 10m loss in 2024. Poland grew 31%, but CEE was under FX pressure (hryvnia -11% versus the zloty), and a weak Q4 (EBITDA -71% YoY) prompted the supervisory board to cut the 2026 EBITDA target from PLN 100m to PLN 90m and the target price from PLN 50 to PLN 45. It is the first full year after MCI's exit from the shareholder base (10 June 2025); the Bajołek brothers retain control (57.8%).
